Equivalence of the 3-month and 28-day formulations of triptorelin with regard to achievement and maintenance of medical castration in women with endometriosis |
| |
Authors: | Donnez Jacques Dewart Paul J Hedon Bernard Perino Antonio Schindler Adolf E Blumberg Joëlle Querleu Denis |
| |
Institution: | a Head of the Department of Gynecology and Andrology, Université Catholique de Louvain, Service de Gynécologie, Brussels, Belgium b Department of Obstetrics and Gynaecology, St John's Hospital at Howden, Livingstone, United Kingdom c Hôpital Arnaud de Villeneuve, Service de Gynécologie-Obstétrique, Montpellier, France d Clinica Ostetrica Ginecologica, Divisione di Ostetricia e Ginecologia, Istituto Materno Infantile, Palermo, Italy e Zentrum für Frauenheilkunde, Universitätsklinikum Essen, Essen, Germany f Beaufour-Ipsen Pharma, Paris, France g Institut Claudius Regaud, Toulouse, France |
| |
Abstract: | ObjectiveThe present study aims at demonstrating the equivalence of the 28-day and 3-month formulations of triptorelin SR (sustained release) in terms of percentage of patients achieving castration levels of estradiol (≤50 pg/mL) 84 days after treatment initiation.DesignA phase II, prospective, randomized, multicenter, open study was conducted in two parallel groups of women with endometriosis.SettingAcademic hospitals.Patient(s)Seventy-two women with endometriosis. were treated with a single intramuscular injection of 3-month triptorelin SR, and 74 patients were treated with one intramuscular injection of 28-day triptorelin SR every 28 days for 3 months.Intervention(s)As part of two parallel treatment groups, 72 women were given a single intramuscular injection of 3-month triptorelin SR, and 74 women were given one intramuscular injection of 28-day triptorelin SR every 28 days for 3 months.Main outcome measure(s)Percentage of patients achieving castration levels of estradiol at the end of the treatment period.Result(s)Patients participated in the study until resumption of menses. Ninety-seven percent of patients given the 3-month formulation and 94% of those given the 28-day formulation were in a state of medical castration on day 84. The mean time to achieve castration was shorter for the 3-month formulation, and the duration of castration was significantly longer. The FSH and LH parameters were comparable, though not always identical.Conclusion(s)The pharmacodynamic effects of the Decapeptyl SR 3-month formulation are equivalent to those of the 28-day formulation. The 3-month formulation provides the added advantage of a longer maintenance of medical castration in women who have endometriosis. |
| |
Keywords: | Medical castration Decapeptyl endometriosis estrogen triptorelin |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|